BioCryst Gains Drug Approval in Canada, Switzerland | North Carolina Biotechnology Center

A drug produced by BioCryst Pharmaceuticals of Durham has won regulatory approval in Canada and Switzerland for preventing hereditary angioedema (HAE), a rare disease of swollen tissues caused by excessive fluid buildup.

Related Keywords

United States ,Canada ,Dublin ,Ireland ,Switzerland ,Canadians ,Swiss ,Canadian ,Henrik Balle Boysen ,Jared Rhines ,Biocryst Pharmaceuticals Of Durham ,Health Canada ,Nasdaq ,Biocryst Pharmaceuticals ,